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Structures of the Apo and FAD-Bound Forms of
2-Hydroxybiphenyl 3-monooxygenase (HbpA) Locate
Activity Hotspots Identified by Using Directed Evolution
Chantel N. Jensen, Tamara Mielke, Joseph E. Farrugia, Annika Frank, Henry Man, Sam Hart,
Johan P. Turkenburg, and Gideon Grogan*[a]
Introduction
Microbial flavoprotein monooxygenases (FPMOs) are involved
in a host of important biochemical processes in a range of
organisms, with many roles in catabolism and natural-product
biosynthesis.[1, 2] Owing to their ability to selectively functional-
ise organic molecules of interest, they also have great potential
as biocatalysts for preparative industrial reactions.[3, 4] A survey
by van Berkel and Fraaije in 2006 divided the FPMOs into six
sub-classes A–F.[3] Subclass “A”, which consists of the aromatic
flavin-dependent hydroxylases, is an attractive group of en-
zymes from the perspective of preparative biocatalysis, as
these enzymes catalyse the selective hydroxylation of aromatic
substrates to phenols, the abiotic preparation of which re-
quires harsh conditions and toxic reagents that are inconsis-
tent with contemporary demands for sustainable chemical syn-
thesis. The model enzyme from subclass “A” has been the
NADPH-plus-FAD-dependent para-hydroxybenzoate hydroxy-
lase (PHBH),[5] which catalyses the hydroxylation of the sub-
strate to 3,4-dihydroxybenzoate (1, Scheme 1), and for which
an X-ray structure[6] and mechanism[7] were first proposed in
1979.
PHBH has served as a model for structural and mechanistic
studies in the aromatic hydroxylases ever since.[8] PHBH and
other class “A” FPMOs are thought to catalyse aromatic hy-
droxylation reactions through a mechanism of two distinct
phases. In the first, the nicotinamide cofactor NAD(P)H is used
to reduce FAD. This reduction is stimulated by the binding of
the aromatic substrate, which acts as an effector. In the second
half of the reaction, reduced FADH2 reacts with molecular
oxygen to produce a C4a-(hydro)peroxyflavin species that acts
as the oxygenating agent in catalysis. Hydroxylation of the aro-
matic nucleus is thought to occur by electrophilic aromatic
substitution, in which the hydroperoxide is the electrophile
and the hydroxybenzoate aromatic ring is the nucleophile.[8]
The nucleophilicity of the aromatic ring is increased by depro-
tonation of the phenolic hydroxy group by active-site residues.
Extensive structural studies on PHBH[9–11] have also revealed
that catalysis is characterised by a mobile flavin that exists in
The FAD-dependent monooxygenase HbpA from Pseudomonas
azelaica HBP1 catalyses the hydroxylation of 2-hydroxybiphen-
yl (2HBP) to 2,3-dihydroxybiphenyl (23DHBP). HbpA has been
used extensively as a model for studying flavoprotein hydroxy-
lases under process conditions, and has also been subjected to
directed-evolution experiments that altered its catalytic proper-
ties. The structure of HbpA has been determined in its apo
and FAD-complex forms to resolutions of 2.76 and 2.03 æ, re-
spectively. Comparisons of the HbpA structure with those of
homologues, in conjunction with a model of the reaction prod-
uct in the active site, reveal His48 as the most likely acid/base
residue to be involved in the hydroxylation mechanism. Muta-
tion of His48 to Ala resulted in an inactive enzyme. The struc-
tures of HbpA also provide evidence that mutants achieved by
directed evolution that altered activity are comparatively
remote from the substrate-binding site.
Scheme 1. Products for some class “A” FPMO aromatic hydroxylases. The hy-
droxy group added by the enzyme indicated is circled. PHBH: para-hydroxy-
benzoate hydroxylase, PHHY: phenol hydroxylase, RdmE: aklavinone-11-hy-
droxylase, HbpA: 2-hydroxybiphenyl 3-monooxygenase.
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different conformations depending on the step in the catalytic
cycle. For flavin reduction, the FAD is displaced away from the
substrate binding site to the periphery of the enzyme (“out”
position), where it can be reduced through interaction with
NAD(P)H. In the presence of substrate, the flavin is located in
the substrate binding site (“in” position). Reduced FADH2 in
the “in” position is able to participate in both the reaction with
oxygen, to form the hydroperoxide, and then the aromatic hy-
droxylation.
In addition to PHBH, other structurally and mechanistically
related class “A” FPMOs that have been characterised range
from phenol hydroxylase (PHHY), which forms catechol (2 ;[12, 13]
Scheme 1), to 3-hydroxybenzoate 6-hydroxylase[14] and biosyn-
thetic enzymes including RebC, which is involved in the pro-
duction of rebeccamycin,[15,16] and aklavinone-11-hydroxylase
(RdmE), which hydroxylates the anthracycline precursor aklavi-
none (3).[17] In 1988, Kohler and co-workers reported the isola-
tion of the bacterium Pseudomonas azelaica HBP1, which was
able to employ as sole carbon source the fungicide 2-hydroxy-
biphenyl (2HBP).[18] The breakdown of the biaryl core was initi-
ated by the ortho-hydroxylation of the substrate to yield 2,3-di-
hydroxybiphenyl (23DHBP). This aromatic hydroxylation was
later attributed to a class “A” FPMO, 2-hydroxybiphenyl 3-mon-
ooxygenase (HbpA), which was isolated and characterised.[19]
Mechanistic studies confirmed that HbpA shared many of the
catalytic characteristics of class “A” FPMOs such as PHBH.[20]
The gene encoding HbpA was cloned and overexpressed in
the heterologous host Escherichia coli[21] to facilitate its applica-
tion to the gram-scale hydroxylation of a range of 2-substitut-
ed phenols[22] and it has also served as a model for the activity
of flavin-dependent hydroxylases under process conditions,
including studies that investigated the stability of the purified
enzyme in the presence of co-solvents such as methanol and
decanol.[23] HbpA was also the subject of successful directed-
evolution experiments that yielded mutants that were superior
to the wild-type in their biotransformation of tert-butyl
phenol[24] guaiacol and 2-sec-butylphenol,[25] displayed im-
proved coupling of NADH oxidation to substrate hydroxylation,
and also a mutant capable of the hydroxylation of indole.[26] In
an effort to shed light on the structural consequences of evo-
lution experiments, and also to provide further information on
substrate recognition and mechanism in HbpA, preliminary X-
ray crystallographic studies on the enzyme were performed.[27]
Although crystals were obtained, a solution of the structure
was frustrated by the short lifetime of the crystals within the
X-ray beam; 20 crystals were required to provide a single data-
set. In this report, using a new genetic construct and exploit-
ing advances in X-ray data collection time, we have used
single crystals of HbpA to determine its structure in two forms:
an FAD-bound form that allows characterisation of the active
site, and an apo form that, although lacking flavin, gives extra
information on the location of residues and structure of
mobile loops that are absent from the FAD complex. The struc-
ture of HbpA allows the beneficial mutation sites previously
identified to be put into a tertiary structural context for the
first time, and also provides a robust platform for further pro-
tein engineering of this useful enzyme.
Results and Discussion
Quality of the models
Sub-cloning of the hbpA gene and its expression from the
YSBLIC-3C vector resulted in a protein that is 21 residues
longer than the native protein by virtue of a spacer that leads
from the N-terminal methionine to the histidine tag, and also
incorporates a C3 protease cleavage site. The tag was not re-
moved prior to crystallisation. Protein resulting from this con-
struct gave crystals of both a different space group (P1 rather
than C2) and cell dimensions from those obtained by Meyer
and co- .[27] These crystals had sufficient longevity within the X-
ray beam for a complete dataset to be collected by using one
crystal in each case for the apo form of the enzyme and the
FAD complex. The structure of the apo form was obtained first,
after which it was determined that soaking with 1 mm FAD
was necessary to obtain structural data in which FAD was at
full occupancy within each active site of HbpA. In the apo
form, the amino acid backbone was complete from residues
Ser4 to Arg228, Ala239 to Trp254 and Glu268 to Arg565. The
FAD complex was less complete in each subunit, with density
of a quality sufficient for building present from Ser4 to Gly194,
Ser203 to Asp211, Asp222 to Arg228, then Gly237 to Met243;
Trp250 to Trp254 then Glu268 to Arg585. In each case, the
breaks in electron density corresponded to loop regions be-
tween the seven b-strands of the substrate binding domain
D2, as described in detail below.
Structure of the HbpA monomer
The monomer of HbpA (Figure 1) broadly resembles the class
“A” FPMO aromatic hydroxylases PHHY, RebC and RdmE of
established structure and consists of three domains: an FAD
Figure 1. Monomer of HbpA FAD complex shown in ribbon format. Selected
a-helices are labelled. FAD is shown in sphere format (carbon atoms in
grey), with the isoalloxazine ring bound at the interface between domains
1 and 2. N and C indicate the amino- and carboxy terminus of the mono-
mer.
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nucleotide binding domain (D1) containing residues 4–76, 96–
197 and 295–374; a “middle” domain[17] (D2), composed of res-
idues 77–95, 375–427 and 198–294; and a C-terminal domain
(D3) incorporating a thioredoxin-like fold formed from residues
428–585.
The closest structural homologues of HbpA, as revealed by
analysis using the DALI server[31] are the flavin-dependent
monooxygenase RebC, from Lechevalia aerocologines (PDB ID:
4EIP; 28% sequence identity; Z-score 39.8; rmsd 2.6 æ over
489 backbone Ca atoms),[15, 16] the aklavinone-11-hydroxylase
(RdmE) from Streptomyces purpurascens[17] (PDB ID: 3IHG; 35%
sequence identity; Z-score 39.2; rmsd 2.2 æ over 474 backbone
Ca atoms) and the phenol monooxygenase (PHHY) from Tri-
chosporon cutaneum (Z-score 35.2; 1PN0/1FOH; 22% sequence
identity; rmsd 2.9 over 476 backbone Ca atoms).[12,13]
The FAD binding domain, D1, is a Rossman-type domain
with a central mixed b-sheet of six strands, bordered by an ad-
ditional sheet of four strands, on the side nearest the enzyme
periphery, and four substantial a-helices (a1, a6, a10 and a11)
at the interface with the thioredoxin domain, D3. The loop of
amino acids 35–52 between strand b2 and helix a2 runs
behind, and provides close contacts with, the isoalloxazine
ring of FAD. HbpA lacks the large additional loop region in D1
that is present in PHHY (formed by residues 170–210), which is
also absent in RdmE and which is thought to constitute a “lid”
over the active site of PHHY.[12] The middle domain, D2, con-
sists of a large seven-stranded mixed b-sheet that provides the
floor of the substrate binding site. Poor density in the loops
connecting these strands accounts for the most of the chain
breaks in both the apo and especially the FAD-complex struc-
tures listed above and is indicative of a higher level of mobility
in this region. The sheet is adjacent to a helix-turn-helix-turn-
helix subdomain formed by residues 325–427 of domain D2,
which incorporates helices a12, a13 and a14 (Figure 1) and
which constitutes one of the major structural differences be-
tween HbpA, RebC, RdmE and PHHY. In PHHY, this subdomain
is smaller, lacking the equivalent of a13, and in RdmE is almost
absent, replaced by a loop of only 15 amino acids (RdmE 373–
388). This large sub-domain in HbpA is almost certainly impor-
tant for dimer stabilisation within the HbpA tetramer (vide
infra). Domain D2 is connected by a long loop from amino
acids 428-471 to the thioredoxin domain D3, which, although
of unknown function in FPMOs, is involved in many reciprocal
contacts with the helix-turn-helix-turn-helix region 325–427 in
domain D2 of the neighbouring monomer.
Structure of the HbpA tetramer
Data on the tetrameric assembly observed in the crystal struc-
ture (Figure 2), which were provided by PISA analysis,[32]
appear to provide good evidence for a physiological tetramer,
as suggested previously:[19] the contact area between mono-
mers A and C is 1243 æ2, with a DG value for this interaction of
¢8.5 kcalmol¢1; the values for the dimer formed by monomers
A and D were 1037 æ2 and ¢12.7 kcalmol¢1. There are ten hy-
drogen bonds and 13 salt bridges between the AC pair, and
between the AD pair are 11 and eight, respectively. The AC
dimer is held together by reciprocal interactions between
domain D3 and helix a14 of domain D2, and also by hydrogen
bonds between the Gln102 side chains in the short helices a5
that connect domains 1 and 2. The AD pair is held together by
extensive reciprocal interactions between the N-terminal four-
stranded b-sheets and helices a3 and a6 of domain D1. There
is a large cavity at the centre of the tetramer into which the
side chains of several hydrophilic amino acids of each mono-
mer, including Glu75 and Tyr76, are projected.
The aromatic hydroxylases PHHY[12] and RdmE[17] are report-
ed to exist in solution as a homodimer and a monomer, re-
spectively. The determinants of the AC homodimer interactions
in PHHY (1FOH) are very different from those of the AC dimer
found in HbpA; in the PHHY dimer, much more extensive
reciprocal interactions exist between domains 2 and 3, giving
a contact area of 1900 æ2, as a result of a relative closure of
the AC subunits relative to HbpA. Dimer formation appears to
be assisted in PHHY by a large movement of the loop 170–210
(absent in HbpA) in domain 1 in only one of the monomers
that brings this loop into close contact with its dimer partner.
Interactions between the more stable dimer pair AD of HbpA
(as indicated by DG values) are actually governed by reciprocal
interactions between the D1 domains, which make compara-
tively few interactions in the PHHY AC dimer, as a result of the
extended loop. The structure of D1 appears to be quite well
conserved between HbpA and RdmE, so the reason for the fail-
ure of the latter to oligomerise in an equivalent way to the
HbpA AD dimer is not clear, but the inability to form an HbpA
AC-type dimer might be attributed to its lack of a substantial
subdomain within D2.
Figure 2. Structure of the HbpA tetramer ABCD, shown in ribbon format
with subunits labelled and domains D1, D2 and D3 of each subunit col-
oured in light blue, green and coral, respectively, as in Figure 1. FAD mole-
cules are shown in sphere format, with carbon atoms in grey.
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Comparison of the apo and FAD structures
Although lacking the FAD coenzyme, the apo structure of
HbpA has proved useful in providing information on secondary
structural elements and residues that are missing from the
FAD-complex structure. The overall rmsd between the two
structures is low, at 0.85 æ over 538 backbone Ca atoms, as
would be expected, but there is a pronounced shift in the rela-
tive orientation of domain D2 away from domain D1 as
a result of FAD binding; this results in a more open active site.
In the apo structure, the backbone Ca atoms of Arg242 and
Met243 on strand b15 in D2 closest to FAD, for example, each
move 2.5 æ away from the binding site in a superimposition of
the two structures. The relative shift in domains is coincident
with an absence of some electron density in regions in the
FAD complex compared to the apo structure. These include
density for the loop 195–203 that connects domains D1 and
D2 as well as additional loops between the seven b-strands of
domain D2, including region 245–249 between b15 and b16
and region 213–219 between b13 and b14, which features the
short helix a8 in the apo structure. The reasons for the mobili-
ty of these loops on FAD binding are unclear ; they correspond
neither to substrate entry channels—as proposed, for example,
for RdmE[17]—nor to the region of the protein that would
move as a result of FAD moving to the “out” position, as also
observed in RdmE. The structural reorganisation upon FAD
binding is also manifested in the orientation of the loop be-
tween residues 36 and 49 between b2 and b3, which moves to
accommodate the isoalloxazine ring of FAD.
FAD and NADH binding
In the FAD complex, the flavin is bound within HbpA in the
“in” position described for other class “A” FPMOs. As a conse-
quence of the relative movement of domains D1 and D2, resi-
due Trp293 on strand b17 has moved to shield the isoalloxa-
zine ring of FAD from the solvent. The ADP moiety of FAD is
bound in a pocket near the surface of D1. The adenine ring is
stacked against the side chain of Arg37, with the exocyclic NH2
bonded to the backbone carbonyl of Tyr144. The adenine ring
also makes hydrogen bonds with the peptidic NH groups of
Arg37 and Tyr144. The ribose hydroxy group is H-bonded to
the side chain of Asn36, and the diphosphate bonds to the
peptidic NH groups of Ala17 and Asp313, and also to water
molecules. The ribitol side chain interacts with the side chains
of Asp313, Arg46 and Gln120. The tricyclic isoalloxazine ring of
FAD is bound deeper within the protein at the base of domain
D1 and near the interface with D2, with the isoalloxazine ring
stacked between loop 46–49 preceding strand b3, and loop
319–324 between b21 and a10. The loop above the flavin pro-
vides the side chains of Ser47, which is directly above the cen-
tral FAD ring, and His48, which is discussed in more detail
below. The loop beneath the flavin provides Pro320 and
Met321 (Figure 3A), which also help to form one wall of the
substrate binding pocket, a large hydrophobic cavity whose
other side formed by the seven-stranded b-sheet of domain
D2.
The sheet of domain D2 provides many hydrophobic side
chains to the active site pocket, including Trp97, Met223 and
Trp225. Among the hydrophobic side chains of the active site,
there are also two hydrophilic residues, Arg242 and His48,
which are situated to the front of the plane of the isoalloxazine
ring (Figure 3A). The imidazole ring of His48 is 5.5 æ from the
C4a atom of FAD at which the hydroperoxide is formed. It is
also 4.0 æ from a water molecule to the front and beneath the
FAD ring that is well placed to mimic the hydroxy group of the
hydroperoxide. Putative roles for His48 in the mechanism of
HbpA are discussed in the context of a model complex struc-
ture below.
The structure of HbpA also allows a comparative analysis of
the cofactor binding loop, which contains residues that assist
in discriminating between the nicotinamide cofactors NADH
and NADPH. In NADPH-dependent PHBH, specificity for the
phosphorylated cofactor is thought to be determined largely
by Arg33, Tyr38 and Arg42, with replacement of Tyr38 by an
acidic residue leading to a shift in activity toward NADH.[33] The
equivalent residues in HbpA: Arg37, Ser40 and Ser42 clearly
provide a less positively charged environment for the NADPH
phosphate, but there are no close structurally homologous
acidic residues that suggest that NADH specificity in HbpA is
achieved through carboxylate–ribose hydroxy interactions.
Comparison of the HbpA active site with FPMO homologues
PHHY and aklavinone-11-hydroxylase RdmE
Determination of the structure of HbpA allows its active site to
be compared with that of its closest structural and functional
homologues in an effort to distinguish the determinants of
mechanism and substrate specificity in the enzyme. Despite
numerous attempts at both co-crystallisation and soaking with
both 2HBP and 23DHBP, no ternary complex of HbpA was
forthcoming. We therefore sought to model the product into
Figure 3. A) Detail of HbpA structure in the FAD binding domain, illustrating
the water molecule (red sphere) closest to the C4a atom of the FAD and
acid/base residues including His48, which forms a dyad with Asp117, and
Arg242. The side chains of Met223 and Met321 contribute to the hydropho-
bic environment within the active site. Electron density corresponds to the
omit (Fo¢Fc) map contoured at a level of 3s and refined in the absence of
FAD, the atoms of which have been added subsequently for clarity. B) Super-
imposition of the structures of RdmE and PHHY (1FOH) with all atoms bar
those of the relevant ligands, AK and PH, respectively, removed. The nucleo-
philic carbon atoms, which wil be hydroxylated in each case, superimpose
with each other. These structures have been used to inform the modelling
of the HbpA active site with the product 23DHBP (grey).
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the active site of the enzyme by using PHHY and RdmE as the
bases. Interestingly, in substrate complexes for both PHHY and
RdmE, the nucleophilic carbons of the substrate to be hydroxy-
lated superimpose very well (Figure 3B), at a distance of ap-
proximately 5.3 æ and an angle of approximately 608 down
from the plane of the FAD isoalloxazine ring. This, in addition
to the orientation of the polycyclic ring system in RdmE, has
provided anchoring positions for modelling the HbpA product
23DHBP into the substrate-binding pocket of HbpA.
It might be expected that some conservation of active-site
residues between PHHY and HbpA would be observed, given
the formal similarity of their substrates; of the hydrophobic
side chains in the active site, for example, Met80 (PHHY) is con-
served as Met77 (HbpA). However, for protic residues that in-
teract directly with the phenol hydroxy group in PHHY, and
have thus been implicated in mechanism,[12] Asp54, which is
thought to assist in phenolate stabilisation, is replaced in
HbpA by His48, and Tyr289, which is thought to act as the
proton donor to the FAD peroxo-anion is replaced by Ala240.
Given these differences, it is clear that, despite similarities in
substrate structure, different mechanisms of substrate orienta-
tion and intermediate stabilisation operate in HbpA.
A comparison of the active site of HbpA with that of
RdmE,[17] is also informative in that, in common with HbpA,
this enzyme catalyses the hydroxylation of a polycyclic aromat-
ic substrate. The recognition of a larger hydrophobic substrate
is reflected in the hydrophobic make-up of the substrate bind-
ing channel in both enzymes. In the HbpA model product
complex, the phenyl ring of the product is accommodated in
a hydrophobic pocket formed by the side chains of Pro320,
Met321, Trp225 and Met223, similar to the binding mode of
the polycyclic ring system of aklavinone in RdmE, although the
phenyl ring is rotated 908 relative to the phenol (Figure 3B).
The phenol is in a hydrophobic pocket formed by Ile49 and
Trp97 near the pyrimidinedione ring of FAD.
As with PHHY, the aklavinone substrate is also thought to be
activated by deprotonation in RdmE, which, in this case, is ac-
complished by Tyr224, which forms a hydrogen bond with the
C6 hydroxy group of aklavinone para to the C11 atom. If de-
protonation of the C2 hydroxy group of the substrate is also
to be a significant step in the HbpA mechanism, the only can-
didate residue for deprotonation is His48. However, in the
product model complex of HbpA, His48 is hydrogen bonded
to the new C3-hydroxy group of the product. In the HbpA–
FAD complex, the His48 NE2 atom is 4.0 æ from a water mole-
cule that is itself 3.6 æ from the FAD C4a atom, and ideally
placed to mimic the hydroxy group of a hydroperoxide inter-
mediate. It might be therefore that His48 is the proton donor
to the nascent hydroperoxide, the role thought to be fulfilled
in PHHY by Tyr289. Interestingly, His48 forms a clear dyad with
Asp117 in the second shell of residues around the active site.
The only other hydrophilic residue that is close to the FAD is
Arg242; the terminal guanidinium group is 8.2 æ from the FAD
C4a, but also only 3.6 æ from the imidazole ring of the His48
side chain.
The His48Ala mutant of HbpA is inactive for the
hydroxylation of 2HBP
The location of His48, Asp 117 and Arg242 within the active
site prompted us to make site-directed mutants of HbpA fea-
turing alanine at these positions in order to test the effect of
these mutations on the ability of the enzyme to bind and to
hydroxylate 2HBP. Each of the mutant genes encoding
His48Ala, Asp117Ala and Arg242Ala was expressed at similar
levels in the soluble fraction as compared to the wild-type
(WT). The apparent Km values (Kmapp) for 2HBP for each of the
mutants were then determined (Table 1) by UV spectropho-
tometry, measuring the oxidation of NADH at 340 nm at
increasing substrate concentration, as described by Meyer
et al.[25] Each mutant displayed Michaelis–Menten-type kinetics
with 2HBP, with the WT Kmapp value of 3.3 mm being of a similar
order to that determined by Meyer et al. (2.6 mm).[25] The Kmapp
of His48Ala was approximately the same as for the WT, but
Asp117Ala and Arg242Ala, displayed values approximately 1.7
times greater than WT in each case. Each mutant was clearly
able to oxidise NADH. The maximum rate of NADH oxidation
in these experiments, recorded in the presence of saturating
concentrations of 2HBP (25 mm) was 0.02 s¢1 for the WT
enzyme, but was reduced approximately fourfold for the
His48Ala and Asp117Ala mutants, and eightfold for the
Arg242Ala mutant.
However, the rate of NADH oxidation as approximately the
same for all variants in the absence of substrate; perhaps this
indicates that the ability of 2HBP to act as an effector is com-
promised in each of these mutants.
The rates of NADH oxidation are often not indicative of the
catalytic performance of HbpA with respect to substrate hy-
droxylation, however, owing to the inefficiency of electron-
transfer steps between cofactors and substrate in the mecha-
nism (“decoupling”).[25] The hydroxylation abilities of WT HbpA
and mutant enzymes were therefore assayed by using the ap-
pearance of product on HPLC, as described in the Experimental
Section. When WT HbpA was incubated with 0.5 mm 2HBP and
NADH in threefold excess, the oxygenation to 23DHBP was
complete after 2 h. No conversion to product was obtained for
reactions containing either the His48Ala or Asp117Ala mutants.
For the Arg242Ala mutants, approximately 15% conversion to
the product was obtained after 2 h. The results appear to sug-
gest that both His48 and Asp117 are essential for the oxygena-
tion reaction to occur, but that Arg242 is not. The precise role
of His48 as a possible proton donor awaits the outcome of
other experiments, including the determination of an HbpA
Table 1. Apparent Km values for the 2HBP and NADH oxidase activity of
HbpA variants.
HbpA variant
WT His48Ala Asp117Ala Arg242Ala
Kmapp (HBP) [mm] 3.30.2 3.10.4 5.00.8 4.81.6
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structure in the presence of the substrate or product. The role
of Asp117 might be either merely to orient the correct tauto-
mer of the His48 imidazole ring for catalysis, as in ribonucle-
ase A,[34] or to reduce the pKa of the histidine NE-2 proton,
thereby assisting its function as a catalytic acid. The role of
Arg242 is unclear, but the higher Kmapp observed for this
mutant, coupled with the mobility of the domain bearing this
residue (as revealed by comparison with the apo structure),
suggests that interaction between this residue and the sub-
strate cannot be ruled out. Although the precise role of His48
in catalysis remains unconfirmed, its identification as the major
protic residue near the C4a atom now permits more thorough
investigation of its mechanistic role.
Location of activity hotspots in HbpA
In the absence of structure, HbpA was subjected to directed-
evolution experiments that resulted in mutants capable of hy-
droxylating 2-tert-butylphenol,[24,25] guaiacol[25] and indole.[26]
The structure of HbpA allows the sites of mutations in these
variants to be located for the first time. The variant Val368Ala/
Leu417Phe was reported to have eightfold improved catalytic
efficiency towards guaiacol. Another variant, Ile244Val dis-
played higher activity towards 2-sec-butylphenol, guaiacol and
2-HBP. A model of HbpA constructed by using the structure of
PHHY as a template, placed Val368 and Leu417 near the sur-
face of the HbpA monomer, and within the substrate binding
pocket.[23] Val368 in each subunit is indeed at the periphery of
the HbpA tetramer in helix a11 within the flavin binding
domain D1 (Figure 4A), and superimposes with Ile412 of PHHY,
but is approximately 13 æ from the FAD, with the loop formed
by residues 317–324 between them. Leu417 is one of the first
residues in the long helix a14 that helps to form the larger
substrate binding domain D2 and is actually 27 æ distant from
the FAD molecule (Figure 4B) Leu417 superimposes in the
region of Met438 of PHHY, rather than Val480, as first
thought.[23] Here it makes stabilising hydrophobic interactions
with Val381, Leu385 and Met421, which support the b-sheet
underlying the substrate-binding pocket.
Electron density for Ile244 is absent in the FAD-complex
structure, but the adjacent residue, Met243, places Ile244
within the loop that separates strands b15 and b16 in the b-
sheet underlying the substrate binding pocket (Figure 4C), and
superimposing with residue Leu285 in PHHY, not with the cata-
lytic residue Tyr289 of PHHY within the substrate binding
pocket, as previously suggested.[23] As each of the three mutat-
ed residues is too distant from the FAD binding site to be im-
plicated in catalysis directly, other roles in substrate transport
or active-site access must be considered. Val368 is on helix
a11, which corresponds to region 354–363 in RebC, which is
proposed to act as the gateway for substrate and product in
that enzyme. In HbpA, helix a11 forms one side of a hydropho-
bic channel, the opening of which also includes the mobile
loop 195–203, as revealed by the apo structure. The mobility
in this region of the protein could mean that it serves as
a gateway in HbpA for entry of the aromatic substrate.
Conclusions
Flavoprotein aromatic hydroxylases are promising candidates
for roles in both the preparative hydroxylation of aromatic sub-
strates and in bioremediation processes. The determination of
their structure is a significant advance in being able to inter-
pret the results of in vitro evolution experiments and in in-
forming new protein-engineering experiments. In addition to
providing the first structural perspective on mechanism and
specificity in HbpA, the structure also reveals new avenues for
rational engineering experiments that could be targeted to-
wards improving or altering its activity.
Experimental Section
HbpA gene cloning, expression and protein purification : The
gene encoding HbpA was provided by Bartlomiej Tomaszewski
(Technical University of Dortmund, Germany). The gene was sub-
cloned into the pET-YSBLIC-3C vector, in which cloned genes
become equipped with a sequence encoding an N-terminal His6
tag. The HbpA gene was amplified by PCR from the template plas-
mid by using the primers 5’-CCAGG GACCA GCAAT GTCGA ATTCT
GCAGA AACTG ATGTT CTTAT TGTGG-3’ (forward) and 5’-GAGGA
GAAGG CGCGT TACGC CCTCC CAAGG ATGCT CTTCA C-3’ (reverse).
Following agarose gel analysis of the PCR product, the relevant
band was eluted from the gel by using a PCR Cleanup kit (Qiagen).
The gene was then subcloned into the pET-YSBLIC-3C vector ac-
cording to published techniques.[35] The recombinant plasmid was
Figure 4. Location of activity hotspots in HbpA as identified by directed-evolution experiments by Schmid, Witholt and co-workers.[24–26] A) Detail of HbpA
showing the location of Val368, the mutation of which to Ala resulted in improved activity towards guaiacol. B) Detail showing the location of Leu417, the
mutation of which to Phe also resulted in improved activity towards guaiacol. C) Detail of HbpA showing the location of Met243, adjacent in sequence to
Ile244, the mutation of which to Val resulted in improved activity towards 2HBP, 2-sec-butylphenol and guaiacol. Domains are coloured as in Figure 1.
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used to transform E. coli XL1-Blue cells (Novagen), yielding colonies
that, in turn, gave plasmids by standard miniprep procedures;
these were sequenced to confirm the identity and sequence of the
gene.
The recombinant plasmid containing the HbpA was used to trans-
form E. coli BL21(DE3) cells by using kanamycin (30 mgmL¢1) as an-
tibiotic marker on lysogeny broth (LB) agar. Single colonies from
an agar plate grown overnight were used to inoculate cultures of
LB (5 mL), which were then grown overnight at 37 8C with shaking
at 180 rpm. The starter cultures served as inocula for 1 L cultures
of LB in which cells were grown until the optical density (OD600)
had reached a value of 0.8. Expression of HbpA was then induced
by the addition of isopropyl b-d-1-thiogalactopyranoside (IPTG,
1 mm). The cultures were then incubated at 18 8C in an orbital
shaker at 180 rpm for approximately 18 h. The cells were harvested
by centrifugation for 15 min at 4225g in a Sorvall GS3 rotor in
a Sorvall RC5B Plus centrifuge.
Cell pellets were resuspended in Tris·HCl buffer (20 mL, 50 mm,
pH 7.5) containing NaCl (300 mm ; henceforth referred to as “buf-
fer A”), per litre of cell culture. The cell suspensions were then soni-
cated for 10Õ45 s bursts at 4 8C with 30 s intervals. The soluble
and insoluble fractions were separated by centrifugation for
30 min at 26892g in a Sorvall SS34 rotor. The crude cell lysate
from 1 L cell culture was filtered and then loaded onto a 5 mL His-
Trap FF crude column (GE Healthcare), which was washed with
buffer A. The column was eluted with imidazole (linear gradient of
20–300 mm) over 20 column volumes at a flow rate of
2.5 mLmin¢1. Fractions containing HbpA, as determined by SDS-
PAGE analysis were combined, and the volume was reduced to
yield a protein concentration of 10 mgmL¢1. The concentrated pro-
tein was a deep yellow colour, suggestive of bound oxidised FAD
within the protein.
Protein crystallisation : Crystallisation conditions for HbpA were
determined by using a Mosquito robot (TTP Labtech, Melbourn,
UK) in conjunction with commercially available screens. Trials were
conducted in 96-well plates with sitting-drop format by using
300 nL drops (150 nL protein plus 150 nL precipitant solution). Pos-
itive hits were scaled up in 24-well Linbro dishes by using the
hanging-drop method of crystallisation, with crystallisation drops
containing protein solution (1 mL) and precipitant reservoir (1 mL).
The best HbpA crystals were obtained in drops that contained
PEG 3350 (18%, w/v), KSCN (0.15m) in Bis·Tris propane buffer
(pH 5.5), with a protein concentration of 10 mgmL¢1. Despite the
yellow colour of the protein solution and of the crystals, the occu-
pancy of flavin was found to be poor in the active sites of the
solved structure; this led to the apo structure described above. In
order to obtain a structure with bound FAD, it therefore proved
necessary to soak the HbpA crystals in a solution of the mother
liquor with added FAD (1 mm), as well as 20% ethylene glycol (as
cryoprotectant) for 5 min prior to flash-cooling in liquid nitrogen
for X-ray diffraction analysis. Crystals were tested for diffraction by
using a Rigaku Micromax-007HF X-ray generator fitted with Osmic
multilayer optics and a mar345 imaging plate detector (Mar-
research, Norderstedt, Germany). Those crystals that diffracted to
greater than 3 æ resolution were retained for full dataset collection
at the synchrotron.
Data collection, structure solution, model building and refine-
ment of HbpA : Complete datasets for apo-HbpA and its FAD com-
plex were collected on beamlines I04 and I04-1, respectively, at the
Diamond Light Source (Didcot, UK). Data were processed and inte-
grated by using XDS[36] and scaled by using SCALA[37] within the
Xia2 processing system.[38] Data collection statistics are given in
Table 2. The structure of HbpA was solved by using BALBES,[39]
which selected a monomer of structure PDB ID 3IHG, the aklavi-
none-11-hydroxylase,[17] as a search model. The solution contained
four molecules in the asymmetric unit; this represents one tetra-
mer. The structures were built and refined by using iterative cycles
of Coot[40] and REFMAC[41] employing local NCS restraints in each
case. For the FAD complex of HbpA, the omit maps, after building
and refinement of the protein backbone and side chains, revealed
clear residual density at the active sites, which was successfully
modelled as FAD. The final structures of apo-HbpA and the FAD
complex had Rcryst/Rfree values of 19.1/24.1 and 17.0/20.3, respec-
tively. The structures were validated by using PROCHECK.[42] Refine-
ment statistics are presented in Table 2. The Ramachandran plot
for apo-HbpA showed 93.5% of residues to be situated in the
most favoured regions, in addition 5.6% were allowed and 0.9%
were outlier residues. For the FAD complex, the respective values
were 95.9, 3.4 and 0.7%. Coordinates and structure factors for
both apo-HbpA and the FAD complex have been deposited in
the Protein Data Bank with the accession codes 4CY6 and 4CY8,
respectively.
Site-directed mutagenesis : The mutants of HbpA, His48Ala,
Asp117Ala and Arg242Ala were generated by using a Clontech In-
Fusion kit, according to the manufacturer’s instructions, from the
primers listed in Table 3. Mutants genes were expressed, and pro-
teins were purified according to the methods described above for
the wild-type.
Enzyme assay : Rates of NADH oxidation both without and with
2HBP (the latter for the purposes of determining Kmapp values for
HbpA variants) were determined by UV spectrophotometry using
the method of Meyer et al.[25] HbpA variants were also assayed for
their ability to oxygenate 2HBP, and the reactions were analysed
by HPLC. Each assay contained 2HBP (0.5 mm), NADH (1.5 mm), air-
saturated phosphate buffer (20 mm, pH 7.5) and purified HbpA var-
Table 2. Data collection and resolution statistics for apo-HbpA and the
HbpA–FAD complex.
apo-HbpA HbpA-FAD complex
beamline Diamond I04 Diamond I04-1
l [æ] 0.97949 0.91999
resolution [æ] 85.97–2.76 (2.83–2.76) 59.53–2.03 (2.08–2.03)
space group P1 P1
unit cell
a, b, c [æ] 79.35, 94.67, 99.16 80.00, 96.18, 102.16
a, b, g [8] 115.03, 96.09, 109.59 114.09, 95.80, 109.31
no. of molecules in the 4 4
asymmetric unit
unique reflections 59321 (4372) 146673 (11110)
completeness [%] 97.9 (97.8) 90.0 (92.0)
Rmerge [%] 0.10 (0.48) 0.07 (0.43)
Rp.i.m. 0.10 (0.36) 0.05 (0.35)
multiplicity 2.1 (2.0) 2.3 (2.4)
hI/s(I)i 5.4 (1.6) 7.4 (2.1)
CC1/2 0.99 (0.70) 1.00 (0.69)
overall B factor from the 63 38
Wilson plot [æ2]
Rcryst/Rfree [%] 19.1/24.1 17.0/20.3
rmsd 1–2 bonds [æ] 0.010 0.016
rmsd 1–3 bonds [8] 1.42 1.76
average main chain B [æ2] 60 35
average side chain B [æ2] 64 40
average water B [æ2] 48 40
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iant (1 mgmL¢1) in a total volume of 2 mL. Product evolution was
followed in a time-dependent manner; samples (250 mL) were
taken, and the reaction was stopped by the addition of 10%
perchloric acid (8 mL) after 0, 2, 4, 8 and 24 h. The resulting precipi-
tate was removed by centrifugation at 16300g, for 1 min. The su-
pernatant was then diluted 1:1 with methanol containing phos-
phoric acid (0.1%, w/v). The samples were analysed by HPLC using
a Phenomenex Aqua 3 mm C18 125A column at 40 8C and eluting
at a flow rate of 200 mLmin¢1 with buffer A (20% acetonitrile, 80%
sodium acetate (50 mm), pH 5.0) and buffer B (80% acetonitrile
and 20% sodium acetate (50 mm), pH 5.0). The gradient used was
as follows: 10–40% buffer B (0–5 min); 40–100% buffer B (5 min);
100% buffer B (5–15 min); 100–10% buffer B (15 min); 10% buf-
fer B (15–25 min). 2HBP eluted at tR=11.1 min, and the product
2,3-dihydroxybiphenyl eluted at tR=10.0 min. The substrate and
product concentrations were calculated from calibration curves
obtained under the same conditions. All samples were run in dupli-
cate.
Docking : Automated docking was performed by using AutoDock
Vina 1.1.2.[43] A monomer structure of the FAD complex of HbpA
was prepared by using AutoDock utility scripts. Coordinates for the
product 23DHBP (4) were prepared by using PRODRG.[44] The
active site of HbpA was contained in a grid of 30Õ32Õ24 with
0.375 æ spacing, centred around the catalytic centre (co-ordinates:
¢9.947, 34.123, ¢16.228) which was generated using AutoGrid in
the AutoDock Tools interface. The dockings were performed by
Vina, therefore the posed dockings were below 2 æ rmsd. The
results generated by Vina were visualised in AutoDock Tools 1.5.6
where the ligand conformations were assessed both upon lowest
Vina energy, but also according to criteria established by previous
studies on mechanism and substrate selectivity in this enzyme
class (vide supra).
Acknowledgements
We are grateful to Plymouth Marine Laboratories Applications
Ltd. and the Biotechnology and Biosciences Research Council
(BBSRC) for funding a studentship award to C.N.J. This research
was also supported by a Marie Curie Network for Initial Training
fellowships to A.F. as part of the project BIOTRAINS (FP7-PEOPLE-
ITN-2008-238531). We also thank Bartlomiej Tomaszewski (B.T.),
Dr. Katja Bìhler and Prof. Dr. Andreas Schmid (A.S.) of the Techni-
cal University of Dortmund for their cooperation, including a gift
of the gene encoding HbpA, and B.T. and A.S. for helpful com-
ments on the manuscript. Muhiadin Omar and Dr Jared Cart-
wright of the University of York are also acknowledged for techni-
cal assistance.
Keywords: biotransformations · FAD · flavoprotein ·
hydroxylation · monooxygenases
[1] M. M. E. Huijbers, S. Montersino, A. H. Westphal, D. Tischler, W. J. H. van
Berkel, Arch. Biochem. Biophys. 2014, 544, 2–17.
[2] C. T. Walsh, T. A. Wencewicz, Nat. Prod. Rep. 2013, 30, 175–200.
[3] W. J. H. van Berkel, N. M. Kamerbeek, M. W. Fraaije, J. Biotechnol. 2006,
124, 670–689.
[4] R. D. Ceccoli, D. A. Bianchi, D. V. Rial, Front. Microbiol. 2014, 5, 25
[5] B. Entsch, W. J. van Berkel, FASEB J. 1995, 9, 476–483.
[6] R. K. Wierenga, R. J. de Jong, K. H. Kalk, W. G. J. Hol, J. Drenth, J. Mol.
Biol. 1979, 131, 55–73.
[7] M. Husain, V. Massey, J. Biol. Chem. 1979, 254, 6657–6666.
[8] S. Montersino, D. Tischler, G. T. Gassner, W. J. H. van Berkel, Adv. Synth.
Catal. 2011, 353, 2301–2319.
[9] H. A. Schreuder, P. A. J. Prick, R. K. Wierenga, G. Vriend, K. S. Wilson,
W. G. J. Hol, J. Drenth, J. Mol. Biol. 1989, 208, 679–696.
[10] H. A. Schreuder, J. M. van der Laan, W. G. J. Hol, J. Drenth, J. Mol. Biol.
1988, 199, 637–648.
[11] D. L. Gatti, B. A. Palfey, M. S. Lah, B. Entsch, V. Massey, D. P. Ballou, M. L.
Ludwig, Science 1994, 266, 110–114.
[12] C. Enroth, H. Neujahr, G. Schneider, Y. Lindqvist, Structure 1998, 6, 605–
617.
[13] C. Enroth, Acta Crystallogr. Sect. D Biol. Crystallogr. 2003, 59, 1597–1602.
[14] S. Montersino, R. Orru, A. Barendregt, A. H. Westphal, E. van Duijn, A.
Mattevi, W. J. H. van Berkel, J. Biol. Chem. 2013, 288, 26235–26245.
[15] K. S. Ryan, A. R. Howard-Jones, M. J. Hamill, S. J. Elliott, C. T. Walsh, C. L.
Drennan, Proc. Natl. Acad. Sci. USA 2007, 104, 15311–15316.
[16] P. J. Goldman, K. S. Ryan, M. J. Hamill, A. R. Howard-Jones, C. T. Walsh,
S. J. Elliott, C. L. Drennan, Chem. Biol. 2012, 19, 855–865.
[17] Y. Lindqvist, H. Koskiniemi, A. Jansson, T. Sandalova, R. Schnell, Z. Liu, P.
Mntsl, J. Niemi, G. Schneider, J. Mol. Biol. 2009, 393, 966–977.
[18] H. P. Kohler, D. Kohler-Staub, D. D. Focht, Appl. Environ. Microbiol. 1988,
54, 2683–2688.
[19] W. A. Suske, M. Held, A. Schmid, T. Fleischmann, M. G. Wubbolts, H.-P. E.
Kohler, J. Biol. Chem. 1997, 272, 24257–24265.
[20] W. A. Suske, W. J. H. van Berkel, H.-P. E. Kohler, J. Biol. Chem. 1999, 274,
33355–33365.
[21] M. Held, W. Suske, A. Schmid, K.-H. Engesser, H.-P. E. Kohler, B. Witholt,
M. G. Wubbolts, J. Mol. Catal. B 1998, 5, 87–93.
[22] J. Lutz, V. V. Mozhaev, Y. L. Khmelnitsky, B. Witholt, A. Schmid, J. Mol.
Catal. B 2002, 19–20, 177–187.
[23] A. Schmid, I. Vereyken, M. Held, B. Witholt, J. Mol. Catal. B 2001, 11,
455–462.
[24] A. Meyer, M. Held, A. Schmid, H.-P. E. Kohler, B. Witholt, Biotechnol.
Bioeng. 2003, 81, 518–524.
[25] A. Meyer, A. Schmid, M. Held, A. H. Westphal, M. Rçthlisberger, H.-P. E.
Kohler, W. J. H. van Berkel, B. Witholt, J. Biol. Chem. 2002, 277, 5575–
5582.
[26] A. Meyer, M. Wìrsten, A. Schmid, H.-P. E. Kohler, B. Witholt, J. Biol. Chem.
2002, 277, 34161–34167.
[27] A. Meyer, D. Tanner, A. Schmid, D. F. Sargent, H.-P. E. Kohler, B. Witholt,
Acta Crystallogr. Sect. D Biol. Crystallogr. 2003, 59, 741–743.
[28] R. P. Joosten, T. A. H. Te Beek, E. Krieger, M. L. Hekkelman, R. W. W. Hooft,
R. Schneider, C. Sander, G. Vriend, Nucleic Acids Res. 2011, 39, D411–
D419.
[29] W. Kabsch, C. Sander, Biopolymers 1983, 22, 2577–2637.
[30] C. S. Bond, A. W. Schìttelkopf, Acta Crystallogr. Sect. D Biol. Crystallogr.
2009, 65, 510–512.
[31] E. Krissinel, K. Henrick, J. Mol. Biol. 2007, 372, 774–797.
[32] L. Holm, C. Sander, Science 1996, 273, 595–602.
[33] M. H. M. Eppink, K. M. Overkamp, H. A. Schreuder, W. J. H. Van Berkel, J.
Mol. Biol. 1999, 292, 87–96.
[34] L. W. Schultz, D. J. Quirk, R. T. Raines, Biochemistry 1998, 37, 8886–8898.
Table 3. Primers used to generate site-directed mutants of HbpA.
Variant Primer
His48Ala: For 5’-AGGTC GGCGA TTATC AATCA GCGCA CGATG GAAAT
TCTG-3’
His48Ala: Rev 5’-AGGTC GGCGA TTATC AATCA GCGCA CGATG GAAAT
TCTG-3’
Asp117Ala: For 5’-TACTG TGCGT TGCCG CAGTT GTATT TTGAG CCGAT
GGTG-3’
Asp117Ala: Rev 5’-CGGCA ACGCA CAGTA TCTTG ATGGG CTTGC CAGCT
C-3’
Arg242Ala: For 5’-GCGCT GGCGA TGATT CGGCC CTGGA ATAAG TGGAT
TTG-3’
Arg242Ala: Rev 5’-AATCA TCGCC AGCGC CGCGA CGCCG ACACC ATTG-3’
ChemBioChem 2015, 16, 968 – 976 www.chembiochem.org Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim975
Full Papers
[35] K. E. Atkin, R. Reiss, N. J. Turner, A. M. Brzozowski, G. Grogan, Acta Crys-
tallogr. Sect. F Struct. Biol. Cryst. Commun. 2008, 64, 182–185.
[36] W. Kabsch, Acta Crystallogr. Sect. D Biol. Crystallogr. 2010, 66, 125–132.
[37] P. Evans, Acta Crystallogr. Sect. D Biol. Crystallogr. 2006, 62, 72–82.
[38] G. Winter, J. Appl. Crystallogr. 2010, 43, 186–190.
[39] F. Long, A. A. Vagin, P. Young, G. N. Murshudov, Acta Crystallogr. Sect. D
Biol. Crystallogr. 2008, 64, 125–132.
[40] P. Emsley, K. Cowtan, Acta Crystallogr. Sect. D Biol. Crystallogr. 2004, 60,
2126–2132.
[41] G. N. Murshudov, A. A. Vagin, E. J. Dodson, Acta Crystallogr. Sect. D Biol.
Crystallogr. 1997, 53, 240–255.
[42] R. A. Laskowski, M. W. Macarthur, D. S. Moss, J. M. Thornton, J. Appl.
Crystallogr. 1993, 26, 283–291.
[43] O. Trott, A. J. Olson, J. Comput. Chem. 2010, 31, 455–461.
[44] A. W. Schìttelkopf, D. M. F. van Aalten, Acta Crystallogr. Sect. D Biol. Crys-
tallogr. 2004, 60, 1355–1363.
Received: December 11, 2014
Published online on March 3, 2015
ChemBioChem 2015, 16, 968 – 976 www.chembiochem.org Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim976
Full Papers
